Novel immune suppression strategies to treat steroid-refractory GVHD have been established, including Janus kinase 1/2 (JAK1/2) inhibitors, with demonstrated clinical efficacy, though not all patients will respond3,4. The gene discussed is JAK1; the disease is graft versus host disease.